Media coverage about Medifast (NYSE:MED) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medifast earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the specialty retailer an impact score of 47.2700319564127 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
MED has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Medifast from a “hold” rating to a “buy” rating and set a $79.00 price objective on the stock in a report on Friday, November 10th. DA Davidson began coverage on shares of Medifast in a research note on Wednesday, August 16th. They set a “buy” rating on the stock. BidaskClub upgraded shares of Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. ValuEngine downgraded Medifast from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Sidoti reissued a “neutral” rating and set a $55.00 price objective (up from $49.00) on shares of Medifast in a research report on Thursday, September 21st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Medifast currently has an average rating of “Hold” and an average price target of $69.33.
Medifast (NYSE MED) opened at $66.61 on Monday. The stock has a market capitalization of $794.90, a P/E ratio of 32.81, a P/E/G ratio of 2.05 and a beta of 0.51. Medifast has a fifty-two week low of $38.53 and a fifty-two week high of $71.73.
The company also recently declared a quarterly dividend, which was paid on Thursday, November 9th. Stockholders of record on Friday, September 22nd were given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.92%. The ex-dividend date was Thursday, September 21st. Medifast’s dividend payout ratio is currently 62.75%.
In related news, Director Glenn W. Welling sold 250,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $65.00, for a total transaction of $16,250,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 406,500 shares of company stock valued at $16,278,170. Company insiders own 6.47% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Medifast (NYSE:MED) Earns Media Impact Score of 0.19” was reported by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://weekherald.com/2017/12/04/medifast-med-earns-news-sentiment-score-of-0-19.html.
Medifast Company Profile
Medifast, Inc produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins.
Receive News & Ratings for Medifast Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast Inc and related companies with MarketBeat.com's FREE daily email newsletter.